Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Viruses ; 15(9)2023 09 03.
Article in English | MEDLINE | ID: mdl-37766276

ABSTRACT

Chikungunya virus (CHIKV) is a mosquito-borne virus with significant public health implications around the world. Climate change, as well as rapid urbanization, threatens to expand the population range of Aedes vector mosquitoes globally, increasing CHIKV cases worldwide in return. Epidemiological data suggests a sex-dependent response to CHIKV infection. In this review, we draw attention to the importance of studying sex as a biological variable by introducing epidemiological studies from previous CHIKV outbreaks. While the female sex appears to be a risk factor for chronic CHIKV disease, the male sex has recently been suggested as a risk factor for CHIKV-associated death; however, the underlying mechanisms for this phenotype are unknown. Additionally, we emphasize the importance of including mosquito salivary components when studying the immune response to CHIKV. As with other vector-transmitted pathogens, CHIKV has evolved to use these salivary components to replicate more extensively in mammalian hosts; however, the response to natural transmission of CHIKV has not been fully elucidated.


Subject(s)
Aedes , Chikungunya Fever , Chikungunya virus , Animals , Female , Male , Mosquito Vectors , Chikungunya Fever/epidemiology , Immunity , Mammals
2.
Vector Borne Zoonotic Dis ; 23(2): 57-62, 2023 02.
Article in English | MEDLINE | ID: mdl-36576967

ABSTRACT

Background: Tick-borne diseases (TBDs) represent a significant threat to human health in the United States. Based on reported cases of notifiable TBDs to the Centers for Disease Control and Prevention (CDC) the state of Alabama is no exception, yet previously there has been no active surveillance program in place to comprehensively assess the presence and prevalence of tick vectors and their associated TBD pathogens in Alabama. Here we summarize initial findings from a 4-year survey to address this unmet need. Materials and Methods: Beginning in 2018 and proceeding through 2021, ticks were collected throughout the state of Alabama and pooled before being screened for a panel of TBD pathogens known to circulate in the United States. Results: Consistent with previously reported cases, TBD pathogens associated with anaplasmosis, babesiosis, ehrlichiosis, and spotted fever rickettsiosis were detected in ticks of Alabama. Causative agents for tularemia and Lyme disease were not detected despite previously reported human disease cases. There was also no evidence of Heartland virus despite recent reports of the virus being detected in ticks in Northwestern counties. Conclusions: While these results serve to provide some insights into TBD pathogens associated with ticks in Alabama, they also raise many questions that highlight the need for additional studies and continued surveillance to fully understand the TBD threat to human health in Alabama.


Subject(s)
Ehrlichiosis , Tick-Borne Diseases , Ticks , Humans , Animals , United States , Alabama/epidemiology , Tick-Borne Diseases/epidemiology , Tick-Borne Diseases/veterinary , Ehrlichiosis/epidemiology , Ehrlichiosis/veterinary
3.
J Vector Ecol ; 47(2): 210-216, 2022 12.
Article in English | MEDLINE | ID: mdl-36314676

ABSTRACT

A statewide survey of the tick fauna found on deer, using harvested deer heads as the sample unit, was conducted during the Alabama hunting seasons of 2019-2020 and 2020-2021. Four species of ticks: Ixodes scapularis (n= 936, % of catch 69.1%), Amblyomma americanum (315, 23.2%), Dermacentor albipictus (97, 7.1%), and Amblyomma maculatum (6, 0.4%) were taken from 151 deer heads harvested from 21 deer processing centers (n = 4-17 heads/processor). A total of 87.7% (prevalence) of deer heads had one or more ticks. We used two standard numerical descriptors of tick numbers, abundance, and relative abundance. No significant stepwise regressions (p > 0.05) were found between tick abundance (all ticks, I. scapularis, A. americanum) and the predictor variables of latitude, deer density, season, and year. In addition, the correlation between the abundance of I. scapularis and A. americanum was not significant (p > 0.5). In contrast, the relative abundance of both I. scapularis and A. americanum showed a significant (P < 0.05) relationship with latitude, with the relative abundance of I. scapularis increasing on deer with increased latitude and A. americanum showing the opposite pattern.


Subject(s)
Deer , Ixodes , Tick Infestations , Animals , Tick Infestations/epidemiology , Tick Infestations/veterinary , Alabama/epidemiology
4.
J Vector Ecol ; 47(1): 38-50, 2022 03.
Article in English | MEDLINE | ID: mdl-35366678

ABSTRACT

The last statewide survey of hard ticks in Alabama was in 1972. To address this deficit, we examined the distribution of the medically important species across the state, Ixodes scapularis (Say), Dermacentor variabilis (Say), Amblyomma americanum (L.), and A. maculatum (Koch), between April, 2018 and February, 2021. Collections primarily involved dragging (April to July) and examination of harvested deer (November to February). A total of 2,927 ticks was collected from 110 sites; three species, I. scapularis, A. americanum, and D. variabilis, represented 91.70% of all ticks collected. Amblyomma americanum and D. variabilis were the most common species encountered in drags; I. scapularis dominated deer collections. Dermacentor variabilis was never found on deer, whereas D. albipictus was only found on deer. Stepwise regression (AIC) of drag data was linked to several site variables. Results suggest a linear response along a south (low abundance) to north (high abundance) gradient, in addition to increased abundance at sites with lower temperatures and greater precipitation and canopy cover.


Subject(s)
Deer , Ixodes , Ixodidae , Alabama , Animals
5.
Sci Rep ; 12(1): 3152, 2022 02 24.
Article in English | MEDLINE | ID: mdl-35210462

ABSTRACT

Despite the availability of vaccines and antiviral therapies, seasonal influenza infections cause 400,000 human deaths on average per year. Low vaccine coverage and the occurrence of drug-resistant viral strains highlight the need for new and improved countermeasures. While influenza A virus (IAV) engineered to express a reporter gene may serve as a valuable tool for real-time tracking of viral infection, reporter gene insertion into IAV typically attenuates viral pathogenicity, hindering its application to research. Here, we demonstrate that lethal or even sublethal doses of bioluminescent IAV carrying the NanoLuc gene in the C-terminus of PB2 can be tracked in real-time in live mice without compromising pathogenicity. Real-time tracking of this bioluminescent IAV enables spatiotemporal viral replication tracking in animals that will facilitate the development of countermeasures by enhancing the interpretation of clinical signs and prognosis while also allowing less animal usage.


Subject(s)
Genes, Reporter , Influenza A virus/physiology , Luminescent Measurements , Orthomyxoviridae Infections/metabolism , Animals , Dogs , Female , HEK293 Cells , Humans , Madin Darby Canine Kidney Cells , Mice , Orthomyxoviridae Infections/genetics
6.
Vaccines (Basel) ; 9(4)2021 Apr 02.
Article in English | MEDLINE | ID: mdl-33918409

ABSTRACT

Chikungunya virus (CHIKV) infection can result in chronic and debilitating arthralgia affecting humans in tropical and subtropical regions around the world, yet there are no licensed vaccines to prevent infection. DNA launched virus like particle (VLP) vaccines represent a potentially safer alternative to traditional live-attenuated vaccines; however, fully characterized immunocompetent mouse models which appropriately include both male and female animals for preclinical evaluation of these, and other, vaccine platforms are lacking. Utilizing virus stocks engineered to express mutations reported to enhance CHIKV virulence in mice, infection of male and female immunocompetent mice was evaluated, and the resulting model utilized to assess the efficacy of candidate DNA launched CHIKV VLP vaccines. Results demonstrate the potential utility of DNA launched VLP vaccines in comparison to a live attenuated CHIKV vaccine and identify gender differences in viral RNA loads that impact interpretation of vaccine efficacy and may have important implications for future CHIKV vaccine development.

7.
Biochem Pharmacol ; 182: 114227, 2020 12.
Article in English | MEDLINE | ID: mdl-32966814

ABSTRACT

AR12 is a derivative of celecoxib which no-longer acts against COX2 but instead inhibits the ATPase activity of multiple chaperone proteins, in particular GRP78. GRP78 acts as a sensor of endoplasmic reticulum stress and is an essential chaperone required for the life cycle of all mammalian viruses. We and others previously demonstrated in vitro and in vivo that AR12 increases autophagosome formation and autophagic flux, enhances virus protein degradation, preventing virus reproduction, and prolonging the survival of infected animals. In this report, we determined whether AR12 could act against SARS-CoV-2. In a dose-dependent fashion AR12 inhibited SARS-CoV-2 spike protein expression in transfected or infected cells. AR12 suppressed the production of infectious virions via autophagosome formation, which was also associated with degradation of GRP78. After AR12 exposure, the colocalization of GRP78 with spike protein was reduced. Knock down of eIF2α prevented AR12-induced spike degradation and knock down of Beclin1 or ATG5 caused the spike protein to localize in LAMP2+ vesicles without apparent degradation. HCT116 cells expressing ATG16L1 T300, found in the majority of persons of non-European descent, particularly from Africa, expressed greater amounts of GRP78 and SARS-CoV-2 receptor angiotensin converting enzyme 2 compared to ATG16L1 A300, predominantly found in Europeans, suggestive that ATG16L1 T300 expression may be associated with a greater ability to be infected and to reproduce SARS-CoV-2. In conclusion, our findings demonstrate that AR12 represents a clinically relevant anti-viral drug for the treatment of SARS-CoV-2.


Subject(s)
Antiviral Agents/pharmacology , Heat-Shock Proteins/antagonists & inhibitors , Pyrazoles/pharmacology , SARS-CoV-2/drug effects , Sulfonamides/pharmacology , Virus Replication/drug effects , Animals , Cell Line, Tumor , Chlorocebus aethiops , Endoplasmic Reticulum Chaperone BiP , Female , Humans , Spike Glycoprotein, Coronavirus/biosynthesis , Vero Cells , COVID-19 Drug Treatment
8.
Antiviral Res ; 182: 104875, 2020 10.
Article in English | MEDLINE | ID: mdl-32755661

ABSTRACT

Venezuelan, eastern, and western equine encephalitis viruses (VEEV, EEEV, and WEEV) are mosquito-borne viruses in the Americas that cause central nervous system (CNS) disease in humans and equids. In this study, we directly characterized the pathogenesis of VEEV, EEEV, and WEEV in cynomolgus macaques following subcutaneous exposure because this route more closely mimics natural infection via mosquito transmission or by an accidental needle stick. Our results highlight how EEEV is significantly more pathogenic compared to VEEV similarly to what is observed in humans. Interestingly, EEEV appears to be just as neuropathogenic by subcutaneous exposure as it was in previously completed aerosol exposure studies. In contrast, subcutaneous exposure of cynomolgus macaques with WEEV caused limited disease and is contradictory to what has been reported for aerosol exposure. Several differences in viremia, hematology, or tissue tropism were noted when animals were exposed subcutaneously compared to prior aerosol exposure studies. This study provides a more complete picture of the pathogenesis of the encephalitic alphaviruses and highlights how further defining the neuropathology of these viruses could have important implications for the development of medical countermeasures for the neurovirulent alphaviruses.


Subject(s)
Encephalitis Virus, Eastern Equine/pathogenicity , Encephalitis Virus, Venezuelan Equine/pathogenicity , Encephalitis Virus, Western Equine/pathogenicity , Encephalomyelitis, Equine/pathology , Encephalomyelitis, Venezuelan Equine/pathology , Macaca fascicularis/virology , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Female , Male , Virus Replication
9.
Viruses ; 10(5)2018 05 01.
Article in English | MEDLINE | ID: mdl-29723973

ABSTRACT

The establishment of a well characterized non-human primate model of Zika virus (ZIKV) infection is critical for the development of medical interventions. In this study, challenging Indian rhesus macaques (IRMs) with ZIKV strains of the Asian lineage resulted in dose-dependent peak viral loads between days 2 and 5 post infection and a robust immune response which protected the animals from homologous and heterologous re-challenge. In contrast, viremia in IRMs challenged with an African lineage strain was below the assay’s lower limit of quantitation, and the immune response was insufficient to protect from re-challenge. These results corroborate previous observations but are contrary to reports using other African strains, obviating the need for additional studies to elucidate the variables contributing to the disparities. Nonetheless, the utility of an Asian lineage ZIKV IRM model for countermeasure development was verified by vaccinating animals with a formalin inactivated reference vaccine and demonstrating sterilizing immunity against a subsequent subcutaneous challenge.


Subject(s)
Disease Models, Animal , Macaca mulatta/immunology , Zika Virus Infection/immunology , Animals , Humans , Viral Load , Zika Virus/classification
10.
Chem Biol Interact ; 267: 96-103, 2017 Apr 01.
Article in English | MEDLINE | ID: mdl-27712998

ABSTRACT

Medical countermeasures to treat biothreat agent infections require broad-spectrum therapeutics that do not induce agent resistance. A cell-based high-throughput screen (HTS) against ricin toxin combined with hit optimization allowed selection of a family of compounds that meet these requirements. The hit compound Retro-2 and its derivatives have been demonstrated to be safe in vivo in mice even at high doses. Moreover, Retro-2 is an inhibitor of retrograde transport that affects syntaxin-5-dependent toxins and pathogens. As a consequence, it has a broad-spectrum activity that has been demonstrated both in vitro and in vivo against ricin, Shiga toxin-producing O104:H4 entero-hemorrhagic E. coli and Leishmania sp. and in vitro against Ebola, Marburg and poxviruses and Chlamydiales. An effect is anticipated on other toxins or pathogens that use retrograde trafficking and syntaxin-5. Since Retro-2 targets cell components of the host and not directly the pathogen, no selection of resistant pathogens is expected. These lead compounds need now to be developed as drugs for human use.


Subject(s)
Benzamides/pharmacology , Chlamydiales/metabolism , Ebolavirus/metabolism , Leishmania/metabolism , Ricin/metabolism , Shiga Toxins/metabolism , Thiophenes/pharmacology , Animals , Benzamides/chemistry , Body Weight/drug effects , Chlamydiales/drug effects , Ebolavirus/drug effects , Escherichia coli/metabolism , HEK293 Cells , HeLa Cells , Humans , Injections, Intraperitoneal , Leishmania/drug effects , Mice , Mice, Inbred BALB C , Mitomycin/pharmacology , Models, Animal , RAW 264.7 Cells , Ricin/antagonists & inhibitors , Shiga Toxins/antagonists & inhibitors , Thiophenes/chemistry
11.
Virology ; 415(1): 20-9, 2011 Jun 20.
Article in English | MEDLINE | ID: mdl-21507450

ABSTRACT

The requirement to replicate in both vertebrate and invertebrate hosts is thought to limit the introduction of genetic changes into the genome of arboviruses. Serial passage under laboratory conditions will overcome this limitation allowing for genetic changes to be introduced and affecting the virulence of the virus for animals. In the studies detailed here, the consequence of removing the restriction of alternate replication was demonstrated to be different depending on the virus. Passing Venezuelan equine encephalitis virus in tissue culture cells, eggs or mice resulted in up to 11 nucleotide or amino acid changes but no significant change in the virulence of the virus for mice. Passing Japanese encephalitis virus (JEV) under the identical conditions resulted in as many as 22 nucleotide or amino acid changes that often resulted in improved survival probabilities. For JEV, most genetic changes along with the attenuated phenotype were selected within 5 passes.


Subject(s)
Encephalitis Virus, Japanese/genetics , Encephalitis Virus, Japanese/physiology , Encephalitis Virus, Venezuelan Equine/genetics , Encephalitis Virus, Venezuelan Equine/physiology , Animals , Cell Line , Encephalitis Virus, Japanese/pathogenicity , Encephalitis Virus, Venezuelan Equine/pathogenicity , Encephalitis, Japanese/virology , Encephalomyelitis, Venezuelan Equine/virology , Mice , Mutation , Phenotype , Sequence Analysis, RNA , Serial Passage , Virulence
12.
Virol J ; 7: 23, 2010 Jan 28.
Article in English | MEDLINE | ID: mdl-20109234

ABSTRACT

BACKGROUND: Embryonated chicken eggs (ECE) are sometimes used for the primary isolation or passage of influenza viruses, other viruses, and certain bacteria. For small-scale experiments with pathogens that must be studied in biosafety level three (BSL3) facilities, inoculated ECE are sometimes manipulated and maintained in small egg incubators within a biosafety cabinet (BSC). To simplify the clean up and decontamination of an egg incubator in case of egg breakage, we explored whether ethylene breather bags could be used to encase ECE inoculated with pathogens. This concept was tested by determining embryo survival and examining virus yields in bagged ECE. RESULTS: Virus yields acceptable for many applications were attained when influenza-, alpha-, flavi-, canine distemper-, and mousepox viruses were propagated in ECE sealed within ethylene breather bags. CONCLUSIONS: For many small-scale applications, ethylene breather bags can be used to encase ECE inoculated with various viruses.


Subject(s)
Containment of Biohazards/methods , Disinfectants/pharmacology , Ethylenes/pharmacology , Occupational Exposure/prevention & control , Viruses/growth & development , Viruses/isolation & purification , Animals , Cell Line , Chick Embryo , Chlorocebus aethiops , Humans , Microbial Viability/drug effects , Survival Analysis , Virus Cultivation
13.
PLoS One ; 3(7): e2709, 2008 Jul 16.
Article in English | MEDLINE | ID: mdl-18628938

ABSTRACT

BACKGROUND: The Venezuelan equine encephalitis (VEE) virus replicon system was used to produce virus-like replicon particles (VRP) packaged with a number of different VEE-derived glycoprotein (GP) coats. The GP coat is believed to be responsible for the cellular tropism noted for VRP and it is possible that different VEE GP coats may have different affinities for cells. We examined VRP packaged in four different VEE GP coats for their ability to infect cells in vitro and to induce both humoral and cellular immune responses in vivo. METHODOLOGY/PRINCIPAL FINDINGS: The VRP preparations were characterized to determine both infectious units (IU) and genome equivalents (GE) prior to in vivo analysis. VRP packaged with different VEE GP coats demonstrated widely varying GE/IU ratios based on Vero cell infectivity. BALB/c mice were immunized with the different VRP based on equal GE titers and the humoral and cellular responses to the expressed HIV gag gene measured. The magnitude of the immune responses measured in mice revealed small but significant differences between different GP coats when immunization was based on GE titers. CONCLUSIONS/SIGNIFICANCE: We suggest that care should be taken when alternative coat proteins are used to package vector-based systems as the titers determined by cell culture infection may not represent accurate particle numbers and in turn may not accurately represent actual in vivo dose.


Subject(s)
Encephalitis Virus, Venezuelan Equine/metabolism , Replicon , Animals , Encephalomyelitis, Venezuelan Equine/virology , Enzyme-Linked Immunosorbent Assay , Female , Genetic Vectors , Genome , Glycoproteins/chemistry , Immune System , Mice , Mice, Inbred BALB C , Mutation , Reverse Transcriptase Polymerase Chain Reaction
14.
Curr Opin Pulm Med ; 12(3): 235-9, 2006 May.
Article in English | MEDLINE | ID: mdl-16582680

ABSTRACT

PURPOSE OF REVIEW: In many cases, the specific pathogen responsible for a respiratory infection is not identified and can lead to improper medical treatment, increased duration of illness, and possibly contributes to the development of antibiotic resistance. Molecular-based diagnostic methodologies have significantly improved our ability to identify common respiratory pathogens; these techniques are not useful, however, when a novel pathogen is responsible for the infection and clinicians must rely on differential diagnosis for the treatment of patients. RECENT FINDINGS: New pathogens previously not associated with human infections have been identified in the past few years. In addition, new strains of bacteria and viruses have emerged as the causative agents of pneumonia and acute respiratory distress. Protozoans and saprophytic fungi, which are not normally associated with respiratory infection, have also emerged as respiratory pathogens particularly in individuals with AIDS or in those who are otherwise immunocompromised. SUMMARY: This review discusses the recent literature on newly described respiratory pathogens as well as opportunistic pathogens that can infect the respiratory system of immunocompromised individuals. The studies referenced here reveal the need for expanded laboratory tests and highly trained microbiologists in clinical laboratories worldwide.


Subject(s)
Respiratory System , Respiratory Tract Infections/etiology , Animals , Bacteria/isolation & purification , Eukaryota/isolation & purification , Fungi/isolation & purification , Humans , Respiratory System/microbiology , Respiratory System/parasitology , Respiratory System/virology , Viruses/isolation & purification
15.
Breast Cancer Res Treat ; 82(3): 169-83, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14703064

ABSTRACT

Many tumor-associated antigens (TAAs) represent 'self' antigens and as such, are subject to the constraints of immunologic tolerance. There are significant barriers to eliciting anti-tumor immune responses of sufficient magnitude. We have taken advantage of a Venezuelan equine encephalitis-derived alphavirus replicon vector system with documented in vivo tropism for immune system dendritic cells. We have overcome the intrinsic tolerance to the 'self' TAA rat neu and elicited an effective anti-tumor immune response using this alphavirus replicon vector system and a designed target antigen in a rigorous rat mammary tumor model. We have demonstrated the capacity to generate 50% protection in tumor challenge experiments (p = 0.004) and we have confirmed the establishment of immunologic memory by both second tumor challenge and Winn Assay (p = 0.009). Minor antibody responses were identified and supported the establishment of T helper type 1 (Th1) anti-tumor immune responses by isotype. Animals surviving in excess of 300 days with established effective anti-tumor immunity showed no signs of autoimmune phenomena. Together these experiments support the establishment of T lymphocyte dependent, Th1-biased anti-tumor immune responses to a non-mutated 'self' TAA in an aggressive tumor model. Importantly, this tumor model is subject to the constraints of immunologic tolerance present in animals with normal developmental, temporal, and anatomical expression of a non-mutated TAA. These data support the continued development and potential clinical application of this alphaviral replicon vector system and the use of appropriately designed target antigen sequences for anti-tumor immunotherapy.


Subject(s)
Antigens, Neoplasm/immunology , Disease Models, Animal , Encephalitis Virus, Venezuelan Equine/genetics , Mammary Neoplasms, Experimental/immunology , Replicon/immunology , Vaccines, Synthetic/immunology , Amino Acid Sequence , Animals , Female , Genetic Vectors/immunology , Genetic Vectors/therapeutic use , Humans , Immunization , Mammary Neoplasms, Experimental/therapy , Molecular Sequence Data , Neoplasm Proteins/immunology , Rats , Rats, Inbred F344 , Receptor, ErbB-2/chemistry , Receptor, ErbB-2/genetics , Receptor, ErbB-2/immunology , Self Tolerance
16.
Rev Med Virol ; 12(5): 279-96, 2002.
Article in English | MEDLINE | ID: mdl-12211042

ABSTRACT

Alphaviruses are positive-stranded RNA viruses that have a broad host range and therefore are capable of replicating in many vertebrate and invertebrate cells. The single-stranded alphavirus genome is divided into two ORFs. The first ORF encodes the nonstructural proteins that are translated upon entry of the virus into the cytoplasm and are responsible for transcription and replication of viral RNA. The second ORF is under the control of a subgenomic promoter and normally encodes the structural proteins, which are responsible for encapsidation of viral RNA and final assembly into enveloped particles. Expression vectors have been engineered from at least three alphaviruses in which the structural protein gene region has been replaced by heterologous genes and have been shown to express high levels of the heterologous protein in cultured cells. These RNA vectors, known as replicons, are capable of replicating on their own but are not packaged into virus-like particles unless the structural proteins are provided in trans. Thus, replicons are single cycle vectors incapable of spreading from infected to noninfected cells. Because of these features, alphavirus replicon vectors are being developed as a platform vaccine technology for numerous viral, bacterial, protozoan and tumour antigens where they have been shown to be efficient inducers of both humoral and T cell responses. In addition, as the alphavirus structural proteins are not expressed in vaccine recipients, antivector immune responses are generally minimal, allowing for multiple effective immunisations of the same individual.


Subject(s)
Alphavirus/genetics , Genetic Vectors , Vaccines, DNA , Vaccines, Synthetic , Animals , Communicable Disease Control , Humans , Replicon , Vaccination/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...